MTP - Midatech Pharma plc

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 3:40PM EDT
Stock chart is not supported by your current browser
Previous Close1.2200
Bid1.2100 x 3100
Ask1.2200 x 900
Day's Range1.2000 - 1.2500
52 Week Range1.0300 - 10.9000
Avg. Volume367,017
Market Cap27.518M
Beta (3Y Monthly)3.47
PE Ratio (TTM)N/A
EPS (TTM)-0.8480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results

    Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results

    Midatech Pharma (NASDAQ:MTP) is on a sweet spot this Friday as the business lifted the veil on its most recent clinical trial, yielding results that were commendable.Source: Shutterstock The United Kingdom-based biopharmaceutical organization said it brought in "positive" results after the first in-human study of its diabetes vaccine. The substance in questions is its MTX102 immuno-tolerising candidate that may have the potential of helping the lives of those who suffer from Type 1 diabetes.Midatech's early success in this matter propelled the brand's trading volume forward as 2.9 million shares exchanged hands, which is many times higher than its full-day average of about 88,000 shares. The company conducted the study by bringing forth five Type 1 diabetes patients in the phase 1 study-this study was designed to determine the safety of MTX102.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"MTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported," the company wrote.MTP stock is up about 30.8% during regular trading hours today following this news, lifting the share price to $1.70 per share after starting the day with a price of $1.30 per share. Midatech now has a market cap of roughly $32.46 million.However, the MTP per-share price is still far from its 2019 peak of $7.90 that it experienced back in February 27. More From InvestorPlace * 10 Tech Stocks That Are Still Worth Your Time (And Money) * 7 Stocks Top Investors Are Buying Now * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 10 Stocks to Sell for an Economic Slowdown The post Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results appeared first on InvestorPlace.

  • Benzinga

    Midatech Pharma Rallies On Positive MTX102 Results

    Midatech Pharma PLC-ADR (NASDAQ: MTP ) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Midatech Pharma PLC (NASDAQ: MTP ) shares ...

  • MarketWatch

    Midatech's stock rockets on heavy volume after positive results from diabetes treatment study

    The U.S.-listed shares of Midatech Pharma PLC rocketed 113% on very heavy volume in premarket trading Friday, after the U.K.-based research and development company focused on rare disease products and cancer treatments disclosed "positive" results from a first in-human study of its MTX102 immuno-tolerising vaccine candidate in diabetes. Trading volume topped 2.9 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 88,000 shares. The company had recruited five recently diagnosed Type I diabetes patients in the phase 1 study, which was focused on assessing safety of MTX102. "MTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported," the company said. The stock had tumbled 80.7% over the past 12 months through Thursday, while the S&P 500 has gained 6.8%.

  • Zacks Small Cap Research

    MTP: Strategic Refocusing to Pure-Play R&D Company; Pivotal Study of MTD201 to Commence 2H19…

    The company generated total gross revenue of £1.94 million, which included both collaboration income and grant revenue. The increase was primarily due to loan redemption penalties and other costs associated with repaying the loan agreement with MidCap. In January 2019, Midatech announced a strategic licensing deal with Chinese Medical Systems (CMS) that included an equity investment.


    Four Healthcare Stocks Getting A Boost On Wednesday

    While industries like tech and auto develop innovative technologies for consumers, by and large, people can survive without their devices and their cars, but our health supersedes all else. The unrivaled importance of the healthcare sector comes with the expectation that companies working in the space are prepared to meet the growing demands of patients suffering from a multitude of diseases. If healthcare companies continue to provide the best quality care for their patients, this may, in turn, spark investor excitement.

  • Reuters

    BRIEF-China Medical System Holdings Unit Signs Agreement With Midatech Pharma PLC


  • Simply Wall St.

    Here’s What Münchener Tierpark Hellabrunn AG’s (MUN:MTP) P/E Is Telling Us

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Münchener Tierpark Hellabrunn AG's (MUN:MTP) P/E ratio and reflect Read More...

  • Simply Wall St.

    Why Münchener Tierpark Hellabrunn AG (MUN:MTP) Delivered An Inferior ROE Compared To The Industry

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • Zacks Small Cap Research

    MTP: Converting to R&D Focused Company Through Divestiture of U.S. Commercial Arm…

    Midatech Pharma Plc (MTP) is a biotechnology company with three novel drug delivery technologies that all improve bio-distribution and bio-delivery of drugs. The technologies achieve this via either the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs.